Research and Development: Comparing Key Metrics for United Therapeutics Corporation and Viridian Therapeutics, Inc.

Biotech Giants: A Decade of R&D Investment Trends

__timestampUnited Therapeutics CorporationViridian Therapeutics, Inc.
Wednesday, January 1, 2014242549000293000
Thursday, January 1, 20152450980001002000
Friday, January 1, 2016147600000888000
Sunday, January 1, 201726460000019623000
Monday, January 1, 201835790000030421000
Tuesday, January 1, 2019118260000034794000
Wednesday, January 1, 202035770000028304000
Friday, January 1, 202154010000056886000
Saturday, January 1, 2022322900000100894000
Sunday, January 1, 2023408000000159765000
Loading chart...

Unleashing insights

A Decade of Innovation: R&D Spending in Biotech

In the ever-evolving world of biotechnology, research and development (R&D) is the lifeblood of innovation. Over the past decade, United Therapeutics Corporation and Viridian Therapeutics, Inc. have demonstrated contrasting trajectories in their R&D investments. United Therapeutics has consistently ramped up its R&D spending, peaking in 2019 with a staggering 1,183% increase from its 2016 low. This commitment underscores their dedication to pioneering treatments and therapies. Meanwhile, Viridian Therapeutics, though starting from a modest base, has shown a remarkable growth trajectory, with R&D expenses surging by over 54,000% from 2014 to 2023. This dramatic rise highlights Viridian's aggressive push into the biotech arena. As these companies continue to innovate, their R&D investments will be crucial in shaping the future of healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025